| Q45138883 | A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma |
| Q38095526 | Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma |
| Q42941866 | An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection |
| Q46981177 | Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? |
| Q26782868 | Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title) |
| Q36301128 | Cure of multiple myeloma -- more hype, less reality. |
| Q46922774 | Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines |
| Q31131493 | Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic |
| Q37039818 | Exercise in patients receiving hematopoietic stem cell transplantation: lessons learned and results from a feasibility study |
| Q24197999 | First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies |
| Q44888557 | Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation |
| Q38771080 | Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review |
| Q38840989 | Immunoselection techniques in hematopoietic stem cell transplantation |
| Q36963203 | Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology |
| Q36502820 | Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases |
| Q47256588 | Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy |
| Q30476207 | Plasmonic nanobubbles as tunable cellular probes for cancer theranostics |
| Q79239990 | Recent publications in hematological oncology |
| Q80764931 | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma |
| Q46829240 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation |
| Q36425946 | Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug |
| Q37616117 | Stem cell mobilization is life saving in an animal model of acute liver failure |
| Q35692626 | Stem cell transplantation for multiple myeloma |
| Q36852229 | Stem cell transplantation for multiple myeloma: current and future status |
| Q39128082 | The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma |
| Q38256923 | The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q35103643 | The war on cancer: a report from the front lines |
| Q35291809 | Therapy strategies for multiple myeloma: current status |
| Q46600713 | Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma |